PD-1 Round-Up: Bristol's Lead Grows, But Field Could Soon See Major Change
Executive Summary
Leading sponsors of PD-1/L1 checkpoint inhibitors looked back on a string of successes and ahead toward the future for combinations with a wide range of other targets during full-year earnings calls.